Ascletis Pharma (HKG:1672) updated its allotment and use of proceeds from its global offering of which HK$1.01 billion of the net proceeds, a 33.9% of the total net proceeds, still remains with the company as of June 30, a Monday filing with the Hong Kong Exchange said.
The biotech company will now use 33.7% of the remaining proceeds for the continued research and development of ASC22, ASC11, and ASC10, and other pipeline products used in the treatment of viral hepatitis, HIV/AIDS, and other viruses as compared with the initial allotment of 45% as reported in the company's 2023 annual report.
To support the research and development of new pipeline drug candidates of the group, the company has allocated 30.8% to it instead of the original 10% share.
The company has increased its allocation to the general working capital to 9.9% as compared with the original 5%.
The company expects to use the reallocated funds in three years starting from Dec. 31, 2023.
The company's shares closed over 4% higher on Tuesday.
Price (HKD): $1.00, Change: $+0.040, Percent Change: +4.17%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.